Metraipolis › archive › dc_fe25d1c798e4
Neurological adverse events of ROS1 inhibitors for non-small cell lung cancer: data from the FDA adverse event reporting system — Europe PMC PMID:41586108
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41586108
- DOI
- 10.3389/fneur.2025.1691324
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T23:12:20.205Z
- SHA-256 of the archived text
712c53c8a17789d97f89d2da0769b3ca8d30e603b57762b09966914c9662a8d9- Stable URL of this page
https://metraipolis.com/documento/dc_fe25d1c798e4
How to cite
Neurological adverse events of ROS1 inhibitors for non-small cell lung cancer: data from the FDA adverse event reporting system — Europe PMC PMID:41586108 — Europe PMC (en), https://europepmc.org/article/MED/41586108 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fe25d1c798e4 (Metraipolis archive dc_fe25d1c798e4, sha256 712c53c8a17789d97f89d2da0769b3ca8d30e603b57762b09966914c9662a8d9)
BibTeX
@misc{dcfe25d1c798e4,
title = {Neurological adverse events of ROS1 inhibitors for non-small cell lung cancer: data from the FDA adverse event reporting system — Europe PMC PMID:41586108},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41586108},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fe25d1c798e4; sha256 712c53c8a17789d97f89d2da0769b3ca8d30e603b57762b09966914c9662a8d9},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41586108. Agents can read the archived copy with the MCP tool read_document.